US OptionsDetailed Quotes
RXRX241206P12000
- 4.80
- +0.20+4.35%
15min DelayClose Dec 3 16:00 ET
4.80High4.60Low
4.60Open4.60Pre Close4 Volume4 Open Interest12.00Strike Price1.87KTurnover952.87%IV-1.55%PremiumDec 6, 2024Expiry Date4.91Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6092Delta0.0690Gamma1.19Leverage Ratio-0.4619Theta-0.0006Rho-0.73Eff Leverage0.0022Vega
Recursion Pharmaceuticals Stock Discussion
“The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.”
$Recursion Pharmaceuticals (RXRX.US)$
$NVIDIA (NVDA.US)$
Goldman Sachs also pointed out in a previous report that by 2025, investors are expected to shift from AI infrastructure to a broader "t...
$NVIDIA (NVDA.US)$ Gem 💎
overnight 13%
No comment yet